MFNG (MFNG) (Middle Region) Peptide
-
- Target See all Manic Fringe (MFNG) products
- Manic Fringe (MFNG) (MFNG)
- Protein Region
- Middle Region
- Origin
- Human, Mouse
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Sequence
- CKLGGRLQPS PLFHSHLETL QLLGAAQLPE QVTLSYGVFE GKLNVIKLPG
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-Mfng Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- Manic Fringe (MFNG) (MFNG)
- Synonyms
- AW546563 Peptide, MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase Peptide, MFNG Peptide, Mfng Peptide
- Background
-
Glycosyltransferase is involved in the elongation of O-linked ligands to activate Notch signaling. Mfng possesses fucose-specific beta-1,3-N-acetylglucosaminyltransferase activity.
Alias Symbols: AW546563
Protein Size: 321 - Molecular Weight
- 36 kDa
- Gene ID
- 17305
- NCBI Accession
- NM_008595, NP_032621
- UniProt
- O09008
-